Science Explorer Back to mapMap
Discussion
Researcher · Istituti Ospitalieri di Cremona · Italy

Matteo Brighenti

Matteo Brighenti publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Surgery, on topics such as Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Lung Cancer Research Studies.

OpenAlex
World rank
#1,359,517
of 7,710,434 ranked researchers
Rank in Italy
#43,758
of 242,206
Works
74
Citations
2.1k
Citations per work
28.9
h-index
16
i10-index 26Top 33% in Oncology
Matteo Brighenti

What does Matteo Brighenti research?

Matteo Brighenti's work is mostly in Medicine (79%), Biochemistry, Genetics and Molecular Biology (6%).

Health Sciences: 58 works · 78.9% of their workMedicine: 58 works · 78.9% of their workOncology: 28 works · 38.5% of their workPulmonary and Respiratory Medicine: 21 works · 28.4% of their workSurgery: 5 works · 6.7% of their workEpidemiology: 4 works · 5.3% of their workEverything else: 11 works · 14.8% of their workLife Sciences: 5 works · 6.3% of their workBiochemistry, Genetics and Molecular Biology: 5 works · 6.3% of their workCancer Research: 3 works · 3.4% of their workMolecular Biology: 2 works · 2.9% of their workTHEIR WORKMatteo Brighenti74works
Life Sciences6%Health Sciences79%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine5878.9%
  2. Everything else1114.8%
    1. Biochemistry, Genetics and Molecular Biology56.3%
  1. 1Oncology38% of their works
  2. 2Pulmonary and Respiratory Medicine28% of their works
  3. 3Surgery7% of their works
  4. 4Epidemiology5% of their works
  5. 5Cancer Research3% of their works
  6. 6Molecular Biology3% of their works

Research topics

Which keywords describe Matteo Brighenti's research?

The keywords of their largest research topics: Chemotherapy, Targeted Therapy, Clinical Trials, ALK Inhibitors, EGFR Mutations, Immunotherapy, Prognostic Factors and Immune Checkpoint Blockade.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 24 words, with their numbers
  1. Chemotherapy493 topics
  2. Targeted Therapy493 topics
  3. Clinical Trials442 topics
  4. ALK Inhibitors261 topic
  5. EGFR Mutations261 topic
  6. Immunotherapy242 topics
  7. Prognostic Factors242 topics
  8. Immune Checkpoint Blockade231 topic
  9. PD-1 and PD-L1231 topic
  10. Molecular Characterization202 topics
  11. Survival Analysis202 topics
  12. Genomic Profiles181 topic
  13. Small-Cell Lung Cancer181 topic
  14. Cetuximab171 topic
  15. KRAS Mutations171 topic
  16. Endoscopic Resection141 topic
  17. Gastric Cancer141 topic
  18. Genetic Mutations122 topics
  19. Metastatic61 topic
  20. Neuroendocrine Tumors61 topic
  21. Pancreatic Neuroendocrine Tumors61 topic
  22. Renal Cell Carcinoma61 topic
  23. Cancer Genomics51 topic
  24. Mutational Signatures51 topic

Where does Matteo Brighenti work?

Matteo Brighenti's main affiliation in the publication record is Istituti Ospitalieri di Cremona, Italy.

How many publications and citations does Matteo Brighenti have?

OpenAlex counts 74 works and 2,141 citations for Matteo Brighenti, an h-index of 16, ranking #1,359,517 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Matteo Brighenti. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.